Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.
MYC
Burkitt lymphoma
CD38
diffuse large B-cell lymphoma
double/triple hit lymphomas
flow cytometry
high grade B-cell lymphoma
large B-cell lymphoma
Journal
Cytometry. Part B, Clinical cytometry
ISSN: 1552-4957
Titre abrégé: Cytometry B Clin Cytom
Pays: United States
ID NLM: 101235690
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
09
07
2018
revised:
21
12
2018
accepted:
22
01
2019
pubmed:
9
2
2019
medline:
1
9
2020
entrez:
9
2
2019
Statut:
ppublish
Résumé
High-grade B-cell lymphomas (HGBCL) with MYC and BCL2 or/and BCL6 rearrangements (R), so-called double/triple-hit lymphomas (DH/THL), are uncommon, clinically aggressive lymphomas that require a prompt diagnosis. We aim to identify flow cytometric immunophenotypic (IP) features of DH/THL that may aid in triaging these cases followed by a timely confirmatory cytogenetic study. We compared the IP features of 43 cases of DH/THL to those of 55 cases of single-hit lymphoma (SHL) and 59 cases of diffuse large B-cell lymphoma (DLBCL) without MYC-R (MYC Bright CD38 expression (CD38 CD38
Sections du résumé
BACKGROUND
High-grade B-cell lymphomas (HGBCL) with MYC and BCL2 or/and BCL6 rearrangements (R), so-called double/triple-hit lymphomas (DH/THL), are uncommon, clinically aggressive lymphomas that require a prompt diagnosis. We aim to identify flow cytometric immunophenotypic (IP) features of DH/THL that may aid in triaging these cases followed by a timely confirmatory cytogenetic study.
METHODS
We compared the IP features of 43 cases of DH/THL to those of 55 cases of single-hit lymphoma (SHL) and 59 cases of diffuse large B-cell lymphoma (DLBCL) without MYC-R (MYC
RESULTS
Bright CD38 expression (CD38
CONCLUSIONS
CD38
Identifiants
pubmed: 30734478
doi: 10.1002/cyto.b.21770
doi:
Substances chimiques
Biomarkers, Tumor
0
Membrane Glycoproteins
0
CD38 protein, human
EC 3.2.2.5
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
368-374Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2019 International Clinical Cytometry Society.
Références
Kluin PM, Harris NL, Stein H, Leoncini L, Campo E, Jaffe ES, Gascoyne RD, Swerdlow SH. High-grade B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press, 2017; p. 335-341.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-2390.
Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, MJ Dyer R, Siebert J, Kuruvilla RK, et al. Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival. Blood. 2009;114:2273-2279.
Dunleavy K. Double-hit lymphomas: Current paradigms and novel treatment approaches. Hematology Am Soc Hematol Educ Program. 2014;2014:107-112.
Swerdlow SH. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: When and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program. 2014;2014:90-99.
Sesques P, Johnson NA. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood. 2017;129:280-288.
Copie-Bergman C. Double-hit DLBCL: Should we limit FISH testing? Blood. 2018;131:1997-1998.
Harrington AM, Olteanu H, Kroft SH, Eshoa C. The unique immunophenotype of double-hit lymphomas. Am J Clin Pathol. 2011;135:649-650.
Platt MY, DeLelys ME, Preffer FI, Sohani AR. Flow cytometry is of limited utility in the early identification of "double-hit" B-cell lymphomas. Cytometry B Clin Cytom. 2013;84B:143-148.
Wu D, Wood BL, Dorer R, Fromm JR. "Double-Hit" mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression. Am J Clin Pathol. 2010;134:258-265.
Maleki A, Seegmiller AC, Uddin N, Karandikar NJ, Chen W. Bright CD38 expression is an indicator of MYC rearrangement. Leuk Lymphoma. 2009;50:1054-1057.
Seegmiller AC, Garcia R, Huang R, Maleki A, Karandikar NJ, Chen W. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol. 2010;23:909-920.
Mandelker DL, Dorfman DM, Li B, Pozdnyakova O. Antigen expression patterns of MYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry. Leuk Lymphoma. 2014;55:2592-2596.
Chen W, Asplund SL, McKenna RW, Kroft SH. Characterization of incidentally identified minute clonal B-lymphocyte populations in peripheral blood and bone marrow. Am J Clin Pathol. 2004;122:588-595.
Pillai RK, Sathanoori M, Van Oss SB, Swerdlow SH. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013;37:323-332.
Cordoba R, Alvarez B, Masso P, Gonzalez FA, Conejo L, Velasco D, Alonso JM, Villarrubia J, Cava F, Llamas P. The utility of multiparametric seven-color flow cytometry in the detection of double hit lymphoma in ascitic fluid samples. Cytometry B Clin Cytom. 2016;90B:543-545.
Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, et al. High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018;131:2060-2064.